151 related articles for article (PubMed ID: 38474751)
21. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.
Vallo S; Michaelis M; Gust KM; Black PC; Rothweiler F; Kvasnicka HM; Blaheta RA; Brandt MP; Wezel F; Haferkamp A; Cinatl J
BMC Res Notes; 2016 Sep; 9(1):454. PubMed ID: 27677700
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
Nordentoft I; Dyrskjøt L; Bødker JS; Wild PJ; Hartmann A; Bertz S; Lehmann J; Orntoft TF; Birkenkamp-Demtroder K
BMC Cancer; 2011 Apr; 11():135. PubMed ID: 21489314
[TBL] [Abstract][Full Text] [Related]
23. Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.
Račkauskas R; Zhou D; Ūselis S; Strupas K; Herr I; Schemmer P
Oncol Rep; 2017 Jun; 37(6):3660-3666. PubMed ID: 28498473
[TBL] [Abstract][Full Text] [Related]
24. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development.
Wu K; Zeng J; Zhou J; Fan J; Chen Y; Wang Z; Zhang T; Wang X; He D
Urol Oncol; 2013 Nov; 31(8):1751-60. PubMed ID: 22421353
[TBL] [Abstract][Full Text] [Related]
25. AKT1/HK2 Axis-mediated Glucose Metabolism: A Novel Therapeutic Target of Sulforaphane in Bladder Cancer.
Huang L; He C; Zheng S; Wu C; Ren M; Shan Y
Mol Nutr Food Res; 2022 Feb; 66(3):e2100738. PubMed ID: 34791822
[TBL] [Abstract][Full Text] [Related]
26. A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.
Sun L; Lu J; Niu Z; Ding K; Bi D; Liu S; Li J; Wu F; Zhang H; Zhao Z; Ding S
PLoS One; 2015; 10(12):e0144484. PubMed ID: 26658059
[TBL] [Abstract][Full Text] [Related]
27. Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.
Meng W; Meng J; Zhang F; Jiang H; Feng X; Zhao F; Wang K
J Physiol Pharmacol; 2021 Oct; 72(5):. PubMed ID: 35158336
[TBL] [Abstract][Full Text] [Related]
28. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells.
Shan Y; Zhang L; Bao Y; Li B; He C; Gao M; Feng X; Xu W; Zhang X; Wang S
J Nutr Biochem; 2013 Jun; 24(6):1062-9. PubMed ID: 23159064
[TBL] [Abstract][Full Text] [Related]
30. Short hairpin RNA targeting FOXQ1 inhibits invasion and metastasis via the reversal of epithelial-mesenchymal transition in bladder cancer.
Zhu Z; Zhu Z; Pang Z; Xing Y; Wan F; Lan D; Wang H
Int J Oncol; 2013 Apr; 42(4):1271-8. PubMed ID: 23403865
[TBL] [Abstract][Full Text] [Related]
31. Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition.
Kyung SY; Kim DY; Yoon JY; Son ES; Kim YJ; Park JW; Jeong SH
BMC Pharmacol Toxicol; 2018 Apr; 19(1):13. PubMed ID: 29609658
[TBL] [Abstract][Full Text] [Related]
32. Expression of beta1-integrins and N-cadherin in bladder cancer and melanoma cell lines.
Laidler P; Gil D; Pituch-Noworolska A; Ciołczyk D; Ksiazek D; Przybyło M; Lityńska A
Acta Biochim Pol; 2000; 47(4):1159-70. PubMed ID: 11996105
[TBL] [Abstract][Full Text] [Related]
33. Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure.
Elie-Caille C; Lascombe I; Péchery A; Bittard H; Fauconnet S
Mol Cell Biochem; 2020 Aug; 471(1-2):113-127. PubMed ID: 32519230
[TBL] [Abstract][Full Text] [Related]
34. TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells.
Jin CY; Molagoda IMN; Karunarathne WAHM; Kang SH; Park C; Kim GY; Choi YH
Toxicol Appl Pharmacol; 2018 Aug; 352():132-141. PubMed ID: 29792947
[TBL] [Abstract][Full Text] [Related]
35. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.
Bindels EM; Vermey M; van den Beemd R; Dinjens WN; Van Der Kwast TH
Cancer Res; 2000 Jan; 60(1):177-83. PubMed ID: 10646871
[TBL] [Abstract][Full Text] [Related]
36. Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction.
Zhao F; Vakhrusheva O; Markowitsch SD; Slade KS; Tsaur I; Cinatl J; Michaelis M; Efferth T; Haferkamp A; Juengel E
Cells; 2020 Dec; 9(12):. PubMed ID: 33316936
[TBL] [Abstract][Full Text] [Related]
37. Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).
Mani J; Vallo S; Rakel S; Antonietti P; Gessler F; Blaheta R; Bartsch G; Michaelis M; Cinatl J; Haferkamp A; Kögel D
BMC Cancer; 2015 Apr; 15():224. PubMed ID: 25885284
[TBL] [Abstract][Full Text] [Related]
38. Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma.
Xie H; Chun FK; Rutz J; Blaheta RA
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073079
[TBL] [Abstract][Full Text] [Related]
39. Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells.
Chen Y; Chen JQ; Ge MM; Zhang Q; Wang XQ; Zhu JY; Xie CF; Li XT; Zhong CY; Han HY
J Nutr Biochem; 2019 Oct; 72():108219. PubMed ID: 31473507
[TBL] [Abstract][Full Text] [Related]
40. miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT.
Zeng T; Peng L; Chao C; Fu B; Wang G; Wang Y; Zhu X
Int J Clin Exp Pathol; 2014; 7(11):7653-62. PubMed ID: 25550801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
